Natixis Amicus Therapeutics, Inc. Transaction History

Natixis

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$9.97 - $14.52 $75,772 - $110,352	7,600 Added 19.17%	47,250 $670,000
Q3 2023 Nov 14, 2023	BUY	$11.78 - $13.86 $466,488 - $548,856	39,600 Added 79200.0%	39,650 $482,000
Q2 2023 Aug 11, 2023	BUY	$10.72 - $13.3 $536 - $665	50 New	50 $0
Q2 2021 Aug 13, 2021	SELL	$8.71 - $10.72 $158,400 - $194,953	-18,186 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$9.2 - $23.86 $896,852 - $2.33 Million	-97,484 Reduced 84.28%	18,186 $180,000
Q4 2020 Feb 12, 2021	BUY	$13.47 - $24.89 $1.56 Million - $2.88 Million	115,670 New	115,670 $2.67 Million
Q1 2019 May 15, 2019	SELL	$10.04 - $13.92 $380,234 - $527,178	-37,872 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$8.38 - $13.44 $20,715 - $33,223	2,472 Added 6.98%	37,872 $363,000
Q3 2018 Nov 14, 2018	SELL	$11.6 - $16.54 $475 - $678	-41 Reduced 0.12%	35,400 $428,000
Q2 2018 Aug 14, 2018	BUY	$13.13 - $17.09 $207,966 - $270,688	15,839 Added 80.8%	35,441 $554,000
Q1 2018 May 15, 2018	SELL	$13.76 - $17.12 $238,171 - $296,330	-17,309 Reduced 46.89%	19,602 $295,000
Q4 2017 Feb 14, 2018	BUY	$12.51 - $16.24 $461,756 - $599,434	36,911	36,911 $531,000

311

312M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.69B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.